key: cord-0947689-q0o46uej
authors: Ryu, Dong-Kyun; Song, Rina; Kim, Minsoo; Kim, Young-Il; Kim, Cheolmin; Kim, Jong-In; Kwon, Ki-Sung; Tijsma, Aloys SL.; Nuijten, Patricia M.; van Baalen, Carel A.; Hermanus, Tandile; Kgagudi, Prudence; Gwete-Moyo, Thandeka; Moore, Penny L.; Choi, Young Ki; Lee, Soo-Young
title: Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant
date: 2021-06-07
journal: Biochem Biophys Res Commun
DOI: 10.1016/j.bbrc.2021.06.016
sha: 7990fd8f173b46e124e7d6516e1b43ea8ce3e611
doc_id: 947689
cord_uid: q0o46uej

The global circulation of newly emerging variants of SARS-CoV-2 is a new threat to public health due to their increased transmissibility and immune evasion. Moreover, currently available vaccines and therapeutic antibodies were shown to be less effective against new variants, in particular, the South African (SA) variant, termed 501Y.V2 or B.1.351. To assess the efficacy of the CT-P59 monoclonal antibody against the SA variant, we sought to perform as in vitro binding and neutralization assays, and in vivo animal studies. CT-P59 neutralized B.1.1.7 variant to a similar extent as to wild type virus. CT-P59 showed reduced binding affinity against a RBD (receptor binding domain) triple mutant containing mutations defining B.1.351 (K417N/E484K/N501Y) also showed reduced potency against the SA variant in live virus and pseudovirus neutralization assay systems. However, in vivo ferret challenge studies demonstrated that a therapeutic dosage of CT-P59 was able to decrease B.1.351 viral load in the upper and lower respiratory tracts, comparable to that observed for the wild type virus. Overall, although CT-P59 showed reduced in vitro neutralizing activity against the SA variant, sufficient antiviral effect in B.1.351-infected animals was confirmed with a clinical dosage of CT-P59, suggesting that CT-P59 has therapeutic potential for COVID-19 patients infected with SA variant.

With the emergence of new variants of SARS-CoV-2, the morbidity and mortality of COVID-19 has been rising again in many countries [1] [2] [3] [4] [5] [6] . For instance, the B.1.1.7 (501Y.V1) variant first described in the UK, and containing a N501Y mutation in the spike protein has spread to more than 100 countries worldwide. Currently, B.1.1.7 has already become the most prevalent virus in European countries such as Germany, France, Italy, and Spain as well as the UK. The second variant of concern (VOC), B.1.351 (501Y.V2) first discovered in South Africa variant, has 9 mutations (L18F, D80A, D215G, Δ242-244, K417N, E484K, N501Y, D614G, and A701V) [7] . This variant dominates the South African epidemic, and is now circulating to neighboring nations in Africa, and local transmission has been observed in European nations and US. Lastly, P.1 (501Y.V3) [8] [14, 15] .

We have developed a COVID-19 therapeutic antibody, CT-P59 which binds to RBD of SARS-CoV-2, interfering with binding to ACE2 (Angiotensin-Converting Enzyme 2), the cellular receptor for viral entry. Also, we have demonstrated that CT-P59 has high potency against the original variant in in vitro and in vivo studies [16] . Here, we evaluated the efficacy of CT-P59 against SA variant via both in vitro binding and neutralization assay with live and pseudoviruses and in vivo challenge experiment in ferrets. 

Binding affinity of CT-P59 to wild type and mutant SARS-CoV-2 RBDs were measured by biolayer interferometry (BLI) using the Octet QK e system (ForteBio) as described previously [17] . All of the mutant SARS-CoV-2 RBDs (K417N, E484K, N501Y and triple mutant) were purchased from Sino Biological.

J o u r n a l P r e -p r o o f ELISA was performed as described previously [17] . In brief, Recombinant RBD or triple mutant proteins were coated onto 96-well, high-binding plates. Following blocking, serially diluted CT-P59 were incubated, followed by an anti-human horseradish peroxidaseconjugated antibody. The signal was developed with TMB substrate (Thermo Fisher Scientific) and absorbance at 450 nm was measured.

Pseudovirus assay was performed as described previously [17] . In short, pseudovirus and serially diluted CT-P59 were incubated and the cells were added. After incubation, luminescence was measured using PerkinElmer Life Sciences Model Victor X luminometer. Neutralization was measured as described by a reduction in luciferase gene expression after single-round infection of 293T/ACE2.MF cells with spike-pseudotyped viruses.

To assess the susceptibility of SARS-CoV-2 variants, a microneutralization assay was performed which was based on the ViroSpot technology described earlier [18] . Briefly, approximately 100 infectious units of virus was mixed with ten 3-fold serial dilutions CT-P59.

The virus/CT-P59 mixture was incubated for 1 h prior to addition to the Vero E6 cells. After a subsequent 1 h incubation, the inoculum was removed, and 1% carboxymethylcellulose (CMC) overlay was added. The plates were incubated for a duration of 16-24 hours at 37°C and 5% CO 2 . The cells were formalin-fixed and ethanol permeabilized followed by incubation with a murine monoclonal antibody which targets the viral nucleocapsid protein (Sino Biological), followed by a secondary anti-mouse IgG peroxidase conjugate (Thermo Scientific) and TrueBlue (KPL) substrate. This formed a blue precipitate on nucleocapsidpositive cells. Images of all wells were acquired by a CTL Immunospot analyzer, equipped J o u r n a l P r e -p r o o f with Biospot ® software to quantitate the nucleocapsid-positive cells (= virus signal). The IC50 was calculated according to the method described earlier [19] .

The animals were housed in BSL3 facility within Chungbuk National University (Cheongju, Korea) with 12 h light/dark cycle with supplied to water and food. All animal cares were performed strictly following the animal care guideline and experiment protocols approved by Institutional Animal Care and Use Committee (IACUC) in Chungbuk National University (CBNUA-1473-20-01)

Groups of 14-to 16-month-old female ferrets (Mustela putorius furo, n=6/group) were sourced from ID.BIO, Corp., Korea. All ferrets, which are seronegative for SARS-CoV-1 and SARS-CoV-2, were inoculated intranasally and intratracheally with 10 5.5 TCID 50 of wild type and B.1.351, respectively, while under anesthesia. Two doses of CT-P59, 80 mg/kg and 160 mg/kg, were administered intravenously 24 h after virus inoculation in treatment groups.

Animals in the control group were given vehicle control. Viral load was measured from nasal wash and lung as the representative for upper and lower respiratory tract. Body weight was daily measured and clinical signs were observed throughout the study. Cough, rhinorrhea and movement were scored and analyzed for each animal in blind manner.

The viral loads in nasal washes and lungs were determined via qRT-PCR and TCID 50 as previously described [16] . Briefly, Viral RNA was extracted and cDNAs were generated.

Viral copy numbers were determined by real-time qRT-PCR with SARS-CoV-2-specific primer set. Real-time PCR reactions were performed using a SYBR Green Supermix (Bio-Rad) and a CFX96 Touch Real-Time PCR Detection System (Bio-Rad). Viral titers for samples from the upper and lower airway were quantitated via TCID 50 which is determined according to the method of Reed and Muench [20] . Virus titer and viral RNA from animals were analyzed using GraphPad Prism v 9.1.0.

To assess the efficacy of CT-P59 against SA variant, we determined the binding affinity of CT-P59 against individual and triple mutant RBDs (K417N, E484K, N501Y, and K417N/E484K/N501Y), which define the SA variant, by using BLI. The equilibrium dissociation constant (K D ) of CT-P59 against K417N was equivalent to that against wild type.

K D values of CT-P59 were reduced by approximately 2-, 2-, and 10-fold in E484K, N501Y, and triple mutant (K417N/E484K/N501Y), respectively (Table 1 ). In addition, ELISA showed that CT-P59 had reduced binding affinity against a triple mutant RBD, compared to wild type ( Fig. 1A in a relevant animal model whether it is affected by the reduced potency observed in vitro.

To demonstrate the in vivo antiviral efficacy of CT-P59 against B.1.351, we conducted virus challenge studies in the ferret animal model. Dose of 160 mg/kg for ferret was selected as clinically relevant dose by conversion from the clinical dose of 40 mg/kg based on the identical exposure to CT-P59 in ferrets. Then, 80 mg/kg was additionally selected as a half dose. Since the initial exposure to therapeutic antibody during the early period of treatment is important factor to prevent from the worsening of infectious disease [21] , the dose conversion between human and ferret was based on the exposure for first three days (AUC 0-72hr ) (data not shown).

The animals challenged with B.1.351 showed significantly reduced viral RNA in nasal washes and lung following CT-P59 treatment (Fig. 2 A and B) . In nasal washes, viral RNA at both 80 mg/kg and 160 mg/kg of doses were decreased by 2.97 log 10 /mL compared to the control one day after CT-P59 administration (2 dpi). In lungs, even though viral RNA of all animals including control animals at 4 dpi had declined to BLQ (below the limit of quantitation), there was a significant decrease in both treatment groups at 2 dpi (1.30 log and 1.57 log reduction for 80 mg/kg and 160 mg/kg, respectively) compared to the control group.

The infectious virus titer (TCID 50 ) in nasal washes and lungs was also significantly decreased in animals treated with CT-P59 when compared to controls, and the infectious virus of B.1.351 was not detected in nasal washes from 2 dpi, with the exception of one animal in the 160 mg/kg treatment group at 2 dpi (Fig. 2 C and D) . In lungs, virus was not detected from 2 dpi in both treatment groups, and the virus titer of control group was also not detected at 4 J o u r n a l P r e -p r o o f dpi. As expected, the animals challenged with wild type virus also showed significant reduction in viral RNA following CT-P59 treatment in nasal washes, and in lung (Fig.2 E and   F ). The infectious virus titer (TCID 50 ) in nasal wash and lung was also significantly decreased in animals treated with CT-P59 when compared to controls (Fig. 2 G and H) .

Ferrets challenged with either B.1.351 or wild type showed a decrease in body weight by about 5% in the control group, while there was no weight loss in the CT-P59 administered groups ( Supplementary Fig. 1 ). There were minimal to mild clinical symptoms after CT-P59 administration until 3dpi; however, no clinical signs were observed from 4 dpi, except one animal challenged with SA variant (Supplementary Table 5 

Here, we have demonstrated the therapeutic potential of neutralizing antibody CT-P59 against which means it could represent of patients with asymptomatic to mild symptoms [22, 23] .

Such findings were consistent with the previous literature [16] , thereby, the current study J o u r n a l P r e -p r o o f employed ferrets for the disease model, taking the intended indication of CT-P59 for treating patients with the mild symptoms into account. As expected, ferrets showed the lower virus titer in the lower airway than the upper airway, for the wild type virus. Importantly, viral load of B.1.351 was also lower in the lower airway than the upper airway, and it decreased relatively faster than wild type virus among control groups.

The tendency of viral loads was mostly consistent in viral RNA copy and infectious virus quantitation in the respiratory tract. The viral loads expectedly decreased from one day after CT-P59 administration in ferrets with wild type virus, as previously described in [16] . CT- 

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper respectively. The graphs are shown as means ± SD from six or three animals at each interval, and dashed lines indicate below the limit of quantification (BLQ) as following; 0.3 log 10 copies Log 10 /mL (Nasal wash) and 0.3 log copies/mL (Lung) for qPCR, 0.8 log 10 TCID 50 /mL (Nasal wash) and 0.8 log 10 TCID 50 /g (Lung) for TCID 50 assay. Asterisks indicate statistical significance between the control and each group as determined by one-way ANOVA and post-hoc Dunnett's test. (* indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001, and **** indicates P < 0.0001).

J o u r n a l P r e -p r o o f Table 1 

Analyte Observational clinical symptoms: Cough, rhinorrhea, movement, and activity. Score: 0; normal, 1: occasional, mild reduced activity, 2: frequent, reduced activity. * Scores were measured by observation of clinical symptoms for at least 20 minutes in each group of ferrets based on the following criteria Cough: 0; no evidence of cough, 1; occasional cough, 2; frequent cough (score 2). Rhinorrhea: 0; no nasal rattling or sneezing, 1; moderate nasal discharge on external nares, 2; severe nasal discharge on external nares. Movement: activity: 0; normal movement and activity, 1; mild reduced movement and activity, 2; evidence of reduced movement and activity. 

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7, Nature

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape

Emergence and rapid spread of a new severe acute respiratory syndrome

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera, bioRxiv

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab <em>in vitro</em>, bioRxiv

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016, bioRxiv

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

ViroSpot microneutralization assay for antigenic characterization of human influenza viruses

Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis

Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response

Infection and Rapid Transmission of SARS-CoV-2 in Ferrets

Animal and translational models of SARS-CoV-2 infection and COVID-19

Analytical Sensitivity Comparison between Singleplex Real-Time PCR and a Multiplex PCR Platform for Detecting Respiratory Viruses

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

The role of antibody concentration and avidity in antiviral protection

Comparative in vitro and in vivo assessment of toxin neutralization by anti-tetanus toxin monoclonal antibodies

indicates statistical significance between the control and each group as determined by one-way ANOVA and post-hoc Dunnett's test. (* indicates P < 0.05 in control vs 80 mg/kg and control vs